
The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
Isaac Y. Kim, MD, PhD, MBA, joins to discuss the evolving data surrounding neoadjuvant therapy before radical prostatectomy in prostate cancer.
The Institute for Safe Medication Practices has reported medication errors due to name confusion between dexlansoprazole (Kapidex) and bicalutamide (Casodex).
The Institute for Safe Medication Practices has reported medication errors due to name confusion between dexlansoprazole (Kapidex) and bicalutamide (Casodex).
Dexlansoprazole is used to treat erosive esophagitis and gastroesophageal reflux disease, while bicalutamide is used in combination therapy to treat metastatic prostate carcinoma, and is contraindicated in women. Patients who receive either drug because of a name mixup could experience unintended drug effects or adverse events.
The institute suggests several strategies to avoid name confusion:





